The Burnet Institute is one of the leading Australian organisations studying long COVID. Its recent study argues that long ...

It's been nearly five years since the pandemic started, but COVID-19 doesn't take a break over the holidays. From shopping to ...

Introduction To end the COVID-19 pandemic, the WHO set a goal in 2021 to fully vaccinate 70% of the global population by mid-2022. We projected the COVID-19 vaccination trajectory in 52 African ...

With less than three weeks left to book COVID-19 and flu vaccinations online, NHS chiefs are urging everyone still eligible to get protected – as the latest figures show nearly 25 million vaccines ...

Everything you need to know about getting a Covid-19 vaccination, including specific rules where you live. Fill out your state or city, age, and other applicable factors to see if you are eligible ...

Moderna posted a profit of $13 million, or 3 cents a share, for the quarter, compared to a loss of $3.6 billion a year ago. Analysts had expected a loss of $753 million, or $1.90 a share ...

Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 ...

As the holiday season approaches, public health experts are sounding the alarm about low vaccination rates against the coronavirus, flu and RSV. With gatherings and travel on the rise, many people ...

As the holiday season approaches, public health experts are sounding the alarm about low vaccination rates against the coronavirus, flu and RSV. With gatherings and travel on the rise, many people ...

(Reuters) -Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell the shot to French drugmaker Sanofi.

Vaccination remains critically important, a shield not just against the physical ravages of COVID infection but also against the insidious mental health deterioration that can follow in its wake.